On this page
Central precocious puberty (MKRN3)
Central precocious puberty, often associated with changes in the MKRN3 gene, leads to early sexual development in children. This can affect growth plates and final adult height, and it typically requires clinical assessment and management.
Overview
Central precocious puberty (CPP) is characterised by the early onset and progression of puberty. In girls, this means the development of breast buds before the age of 8 years, and in boys, testicular enlargement before the age of 9 years. CPP is considered 'central' because it involves the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, which is the system in the brain responsible for regulating sexual development [PMID:33651152].
While many cases of CPP do not have an identified genetic cause, some forms are linked to specific gene changes. One such form is associated with alterations in the MKRN3 gene, and this is considered one of the more common genetic causes of central precocious puberty [PMID:24151240]. Early diagnosis and management are important to address potential effects on a child's growth and social development.
Symptoms & clinical features
The primary symptoms of central precocious puberty are the physical signs of sexual maturation. In girls, this typically begins with breast development (thelarche), followed by pubic or underarm hair growth (pubarche), and later, menstrual periods (menarche). In boys, the first sign is usually an increase in testicular size, followed by pubic and underarm hair growth, deepening of the voice, and penile enlargement.
Alongside these obvious physical changes, children with CPP may experience a rapid increase in height (a 'growth spurt'), which is a normal part of puberty. However, because puberty starts early, the growth plates in their bones can fuse prematurely, potentially leading to a shorter final adult height than predicted. Behavioural changes may also be observed, although these are not specific to the condition [PMID:33651152].
Video: Genetics 101
Affected organs
Central precocious puberty primarily affects the endocrine system, specifically the hormones produced by the hypothalamus, pituitary gland, and gonads (ovaries in girls, testes in boys). The premature activation of this axis leads to the early maturation of the gonads.
While the condition itself is endocrine, the physical manifestations affect other body systems. Early bone maturation (leading to potential reduced adult height) impacts the skeletal system. The development of secondary sexual characteristics affects the reproductive organs and associated tissues.
Risks & severity
The severity of central precocious puberty varies, but the main risks are related to the physical and potential psychological effects of early sexual development. The rapid skeletal maturation can reduce a child's final adult height. There may also be psychosocial challenges, such as feeling different from peers, which can affect self-esteem and social interactions.
For females, some research suggests a potential association between earlier menarche and slightly increased risks for certain adult health conditions later in life, though this is an area of ongoing study. The age of onset for MKRN3-related CPP typically follows the general definitions for precocious puberty, meaning before age 8 in girls and age 9 in boys.
Genetic causes
Central precocious puberty can be caused by changes in certain genes. One significant gene associated with this condition is MKRN3, which stands for 'makorin ring finger protein 3'. The MKRN3 protein is thought to play a role in regulating the onset of puberty. Normally, MKRN3 acts to suppress the activity of the reproductive hormone pathway before the appropriate age for puberty.
When there is a pathogenic variant (a genetic change) in the MKRN3 gene, it can disrupt the protein's normal function. This loss of function means the "brake" on puberty is released too early, leading to the premature activation of the HPG axis and the onset of central precocious puberty [PMID:24151240]. The MKRN3 gene is inherited in an imprinted manner, which means that only the copy inherited from one parent (the father in this case) is active.
- MKRN3 makorin ring finger protein 3
Inheritance pattern
Central precocious puberty linked to MKRN3 is inherited in an autosomal dominant (imprinted) manner. 'Autosomal dominant' means that only one copy of the altered gene is enough to cause the condition. 'Imprinted' means that whether the gene change causes symptoms depends on which parent the altered gene was inherited from. In the case of MKRN3, only the copy inherited from the father is active; the copy inherited from the mother is naturally silenced [PMID:24151240].
This means that if a child inherits an altered MKRN3 gene from their father, they are at risk of developing central precocious puberty. If they inherit the same altered gene from their mother, they are typically unaffected but can still pass the altered gene to their children. Each child of an affected father (or a mother who carries the variant) has a 50% chance of inheriting the altered gene. Genetic counselling can provide more detailed information about inheritance patterns and risks for family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of central precocious puberty typically begins with a clinical assessment by a paediatric endocrinologist. This involves a physical examination to check for signs of puberty, along with reviewing growth charts and bone age X-rays to assess skeletal maturity. Blood tests are performed to measure hormone levels, such as luteinising hormone (LH), follicle-stimulating hormone (FSH), and sex steroids (oestradiol in girls, testosterone in boys), both at baseline and after stimulation testing (e.g., GnRH stimulation test) [PMID:33651152].
If these tests confirm CPP, genetic testing may be considered, especially if there is a family history of early puberty or if other causes have been ruled out. Genetic testing for MKRN3 variants falls under the NHS Genomic Medicine Service (GMS) pathways. Referrals for genetic testing are typically made by a specialist paediatrician or endocrinologist to a regional clinical genetics service. This testing would be guided by an appropriate R-code, facilitating a comprehensive genetic analysis.
Management & lifestyle
Management of central precocious puberty in the UK typically involves a multidisciplinary approach, guided by a paediatric endocrinologist. The primary aim of treatment is often to halt or reverse the progression of puberty and to preserve adult height potential. This is often achieved through medication that suppresses the HPG axis, such as GnRH analogues, which are given as injections, typically monthly or every three months.
Regular monitoring of growth, bone age, and hormone levels is essential to assess the effectiveness of treatment. Psychological support may also be offered through the NHS or related services to help children and families cope with the social and emotional aspects of early puberty. Lifestyle considerations, such as a balanced diet and regular exercise, are important for general health. Genetic counsellors can provide crucial support and information regarding the genetic aspects of the condition and family planning.
UK care pathway
In the UK, suspected cases of central precocious puberty are usually referred by a GP to a paediatrician, who may then refer to a paediatric endocrinologist. If a genetic cause is suspected, the patient may be referred to a clinical genetics service. The NHS Genomic Medicine Service (GMS) provides comprehensive genetic testing, and relevant R-codes are used to guide the appropriate genetic tests for conditions like central precocious puberty. Genetic counsellors within these services play a vital role, offering information, support, and guidance to families navigating a genetic diagnosis.
Frequently asked questions
What is the normal age for puberty to start?
Puberty typically starts between ages 8 and 13 for girls, and between ages 9 and 14 for boys. When puberty begins earlier than these ages, it is considered precocious puberty.
Can central precocious puberty be treated?
Yes, central precocious puberty can often be treated. The most common treatment involves medications called GnRH analogues, which help to slow down or stop the progression of puberty until the child reaches a more typical age for pubertal development.
How does early puberty affect a child's height?
Children with early puberty often experience a growth spurt initially. However, because their bones mature faster, the growth plates can fuse prematurely, which may lead to a shorter final adult height than they might have otherwise achieved.
If I have an MKRN3 variant, will my children definitely have early puberty?
The inheritance of MKRN3 variants is complex due to imprinting. If an altered MKRN3 gene is inherited from the father, there is a risk of developing early puberty. If it is inherited from the mother, children are typically unaffected but can still pass the variant on. Genetic counselling can provide specific risk information for your family.
How do I get genetic testing for central precocious puberty in the UK?
If central precocious puberty is suspected or diagnosed, your paediatrician or endocrinologist can refer you to a clinical genetics service within the NHS. They will assess whether genetic testing is appropriate and guide you through the process, which is covered by the NHS Genomic Medicine Service.